A wild ride for TransThera investors: what’s the story?
The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Zai Lab under pressure over clinical results and rival drugs
9688.HK ZLAB.US
-
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK 688331.SHG
- RNA drug developer Ribo Life targets fresh funding channel
-
Investors pile into CANbridge stock but can the rally last?
1228.HK
